WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva

Vaccine

Volumn 25, Issue 36, 2007, Pages 6557-6564

  Cherian, Thomas ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Conjugate; Serotype composition; Streptococcus pneumoniae; Vaccines

Indexed keywords

MENINGITIS VACCINE; PNEUMOCOCCUS VACCINE;

BACTERIUM CARRIER; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; HERD IMMUNITY; IMMUNOGENICITY; NASOPHARYNX; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH ORGANIZATION;

ANTIBODIES, BACTERIAL; DEVELOPING COUNTRIES; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; WORLD HEALTH ORGANIZATION;

EID: 34547653039     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.044     Document Type: Conference Paper

References (26)

1. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 1 (2000) 100-121
2. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-9):1-35.
3. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54(36):893-7.
4. O'Brien K.L., Shaw J., Weatherholtz R., Reid R., Watt J., Croll J., et al. Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. Am J Epidemiol 160 3 (2004) 270-278
5. Watson M., Bayley K., Bell J.M., Gilbert G.L., Hogg G., Keil A.D., et al. Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002-implications for vaccine serotype coverage. Commun Dis Intell 27 4 (2003) 478-487
6. Invasive Pneumococcal Study Group. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? The Vaccine Impact Surveillance Network-Invasive Pneumococcal Study Group. Med J Aust 173 Suppl (2000) S36-S40
7. Berkley J.A., Lowe B.S., Mwangi I., Williams T., Bauni E., Mwarumba S., et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 352 1 (2005) 39-47
8. Yaro S., Lourd M., Traore Y., Njanpop-Lafourcade B.M., Sawadogo A., Sangare L., et al. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 43 6 (2006) 693-700
9. Leimkugel J., Adams F.A., Gagneux S., Pfluger V., Flierl C., Awine E., et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis 192 2 (2005) 192-199
10. Feikin D.R., and Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35 5 (2002) 547-555
11. Kim N.H., Kim S.H., Lee J.A., Choi E.H., and Lee H.J. Changes of serotype distribution of Streptococcus pneumoniae isolates from children in Korea over a 15 year period, 1991-2005. Final Program and Abstracts, 44th Infectious Disease Society of America. Toronto (2006) 172 [Abstract]
12. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
13. Pai R., Moore M.R., Pilishvili T., Gertz R.E., Whitney C.G., and Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192 11 (2005) 1988-1995
14. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A.L., Hadler J., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 144 1 (2006) 1-9
15. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 3 (2000) 187-195
16. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 9546 (2006) 1495-1502
17. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N., et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 14 (2003) 1341-1348
18. Cutts F.T., Zaman S.M.A., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
19. Goldblatt D., Richmond P., Millard E., Thornton C., and Miller E. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 180 2 (1999) 538-541
20. Eskola J., Olander R.M., Hovi T., Litmanen L., Peltola S., and Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348 9043 (1996) 1688-1692
21. Sturgess A.W., Rush K., Charbonneau R.J., Lee J.I., West D.J., Sitrin R.D., et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 17 9/10 (1999) 1169-1178
22. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 5 (1998) 2093-2098
23. Buttery J.P., Riddell A., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293 14 (2005) 1751-1758
24. World Health Organization. WHO Technical Report Series: recommendations for the production and control of pneumococcal conjugate vaccines, No. 927. 2005;pp. 66-92.
25. Siber G.R., Chang I., Baker S., Fernsten P., O'Brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25 19 (2007) 3816-3826
26. O'Brien K.L., and Nohynek H. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 22 2 (2003) e1-e11